No surprises in results
While the costs and preparations for the Phase 3 studies on NTCD-M3 and XF-73 will continue over the next year, we expect a transition to a lower cash burn after the first Phase 3 starts in 2024. Before then, we forecast another licensing deal (and modest cash in-flows) for Destiny’s second Phase 3-ready product, XF-73.Destiny’s cash at the end of FY 2022 was £4.9m and it estimates that its cash reach extends to H2 2024. Our own forecasts include another $1m upfront payment for the licensing of XF-73 in YE 2023, after which milestones and royalties from both transactions could mean that Destiny avoids returning to the equity markets.
Having successfully executed on the business development front with the licensing of its lead Phase 3-ready product – the non-toxigenic Clostridioides difficile strain M3 (NTCD-M3) for the prevention of C.difficile infections – expectations remain high for its second Phase 3-ready product, XF-73 for the prevention of staphylococcal post-operative infections.
Our fair value for Destiny Pharma has risen modestly to £254.7m (or 279p / share) as a result of the revised cash balance.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.